Moleculin Biotech, Inc. (0K2H)
LSE
Closed
Sep 28, 2026
Day's Range
0.536452 wk Range
0.2405Overview - 0K2H - Moleculin Biotech, Inc.
Key Statistics
Valuation
Enterprise Value
3.41M
P/E (Trailing)
‪1.60‬
Price / Book
‪0.32‬
EV / EBITDA
‪-0.11‬
Profitability
Profit Margin
‪27.69%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-84.56%‬
Return on Equity
‪-1,371.64%‬
Ownership
Shares Outstanding
13.60M
Float
17.03M
Held by Insiders
‪6.12%‬
Held by Institutions
‪8.18%‬
Price stats
Beta
‪1.91‬
50-Day Avg
‪0.5986‬
200-Day Avg
‪0.6455‬
Dividends
Frequency
Annual
Peers - 0K2H - Moleculin Biotech, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0K2HLSEMoleculin Biotech, Inc.-2139.78%52-week change1.61P/E (Trailing)‪27.69%‬Profit Margin
- 0A45LSEModerna Inc.+87.31%52-week change72.95P/E (Trailing)‪11.32%‬Profit Margin
- 0RU5LSEOncoinvent ASA+98.58%52-week change329.17P/E (Trailing)‪34.25%‬Profit Margin
- 0JDKLSEIovance Biotherapeutics Inc.+84.26%52-week change25.49P/E (Trailing)‪-89.09%‬Profit Margin
- 0GQULSEActive Biotech AB+97.84%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0RISLSECircio Holding ASA+94.15%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- 0NWKLSEValerio Tx Corp.+83.69%52-week change0.92P/E (Trailing)‪-190.36%‬Profit Margin
Profile Summary - 0K2H - Moleculin Biotech, Inc.
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
